BioNexus Discovery
BioNexus Discovery
From Data to Discovery
MET
MultiEndpointTox
v2.2.0 OpenTox 2.0 MIT
checking…
API Docs
Research use only — not for clinical or regulatory decisions. Models are trained on limited, imbalanced public datasets and are not clinically validated. Predictions outside the applicability domain are suppressed. Read full limitations

Toxicity Predictions

Multi-endpoint QSAR assessment with Tanimoto applicability-domain gating. Probabilities above each endpoint's calibrated threshold are flagged as positive.

SHAP Feature Attribution

TreeSHAP values show each feature's influence on the model output — directional, not mechanistic. Features are ECFP4 Morgan-fingerprint bits and RDKit descriptors.

Metabolite Screening

SyGMa rule-based prediction of Phase I (oxidation, hydrolysis) and Phase II (conjugation) biotransformation products, ranked by occurrence probability.

Pharmacogenomic Safety Index

PSI across CYP2D6, CYP2C9 and CYP2C19 phenotype bins (PM / IM / EM / UM) per CPIC guidance. Higher risk where metabolizer status alters exposure.

Full Compound Report

Integrated safety profile combining toxicity predictions, interpretability, metabolism and pharmacogenomics.